Homology Medicines, Inc. Stock News

BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstanding share of Homology common stock held by such stockholder as of such record date. The payment date ...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Homology Medicines, Inc. (NasdaqGS: FIXX) with Q32 Bio Inc. Under the terms of the proposed transaction, Homology shareholders will end up owning approximately 25% of the combined company, subject to possible ad...

NEW ORLEANS , Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price Requirement

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Homology Medicines, Inc. (NasdaqGS: FIXX) with Q32 Bio Inc. Under the terms of the proposed transaction, Homology shareholders will end up owning approximately 25% of the combined company, subject to possible ad...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Homology Medicines, Inc. (NASDAQ: FIXX) and Q32 Bio Inc. is fair to Homology shareholders. Upon completion of the proposed transaction, Homology shareholders are expected to own approximately 25% of the combined company. Halper Sadeh encourages Homology shareholders to click here to ...

--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio's two clinical development candidates, bempikibart ( ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders-- --Q32 Bio has re-acquired worldwide development and commercial rights to bempikibart, an an...

--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio's two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders-- --Q32 Bio has re-acquired worldwide development and commercial rights to bempikibart, an ant...